Related Experiment Video
Updated: Jul 6, 2026
Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Enhancing docetaxel efficacy and reducing toxicity using biodegradable periodic mesoporous organosilica nanoparticles
Ha Nguyen Van1,2,3, Linh Ho Thuy Nguyen1,3, Ngoc Xuan Dat Mai4,3
1University of Health Science (UHS), VNU-HCM, Ho Chi Minh City, Viet Nam.
Abstract:
Taxanes, such as docetaxel (DTX), are pivotal in cancer therapy, showcasing remarkable efficacy against various cancers, like breast, lung, and ovarian malignancies. However, DTX's efficacy is hindered by poor target specificity and significant adverse effects. Formulations containing DTX often include polysorbate 80 and ethanol, exacerbating reactions like hypersensitivity and neurological disorders. Nanotechnology offers a promising avenue to address these challenges, aiming to enhance DTX's targeted delivery and solubility. Mesoporous silica nanoparticles (MSN), notably biodegradable periodic organosilane (BPMO), have emerged as promising carriers due to their stability, biocompatibility, and drug-loading capacity. BPMO's intracellular biodegradability reduces the risk of toxic accumulation. Compared to conventional MSN, BPMO particles exhibit superior characteristics, including size, surface area, and DTX loading ability. Moreover, cell line studies suggest BPMO's potential to mitigate DTX-associated adverse effects. These findings highlight BPMO nanoparticles' potential in improving DTX delivery, solubility, and reducing adverse effects, underscoring their significance in cancer therapy.
Insights
Biodegradable periodic organosilane nanoparticles (BPMO) offer improved docetaxel (DTX) delivery for cancer therapy. These novel nanoparticles enhance DTX solubility and reduce adverse effects, showing promise for improved patient outcomes.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Docetaxel (DTX) is a key chemotherapy agent, but its effectiveness is limited by poor targeting and severe side effects.
- Current DTX formulations can cause hypersensitivity and neurological issues due to excipients like polysorbate 80 and ethanol.
Purpose of the Study:
- To evaluate biodegradable periodic organosilane nanoparticles (BPMO) as a drug delivery system for docetaxel (DTX).
- To assess BPMO's potential to improve DTX solubility, targeting, and reduce associated toxicities in cancer therapy.
Main Methods:
- Synthesis and characterization of BPMO nanoparticles.
- Evaluation of DTX loading capacity and solubility within BPMO carriers.
- In vitro studies using cancer cell lines to assess efficacy and safety profiles.
Main Results:
- BPMO nanoparticles demonstrated superior size, surface area, and DTX loading capacity compared to conventional mesoporous silica nanoparticles (MSN).
- Intracellular biodegradability of BPMO minimizes toxic accumulation risks.
- Cell line studies indicated BPMO's potential to mitigate DTX-induced adverse effects.
Conclusions:
- BPMO nanoparticles represent a promising platform for enhancing docetaxel delivery in cancer treatment.
- This nanotechnology approach shows potential for improving drug solubility, targeted delivery, and reducing the toxicity of DTX therapy.
